The severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused the ongoing COVID-19 pandemic, infecting more than 206 million people and causing upwards of 4.34 million deaths at the time of writing.
When screening for novel drugs and accessing drug effectiveness against viruses, automated high-throughput imaging with the Celigo Image Cytometer can have significant advantages in speed, accuracy, and cost over other methods.
Taking Advantage of Viral Cytopathic Effects to Aid in the Rapid Screening of Effective Viral Therapies
Virology researchers use CPE effects pathogens elicit on the host to study host-pathogen interactions.
The COVID-19 pandemic has increased SARS-CoV-2 research globally resulting in three publicly available vaccines from Moderna, Pfizer (mRNA-based), and Johnson & Johnson (viral vector-based).
Many leading labs in the field of virology have used the Celigo Image Cytometer to directly measure multiplex cell-based assays in real-time.
The Celigo Image Cytometer reduces assay time while providing richer, quantitative readouts to accelerate assessment of vaccine and antiviral compound candidates.
There are many methods to determine a viral titer, with each having its pros and cons, however the increasing need to have high throughput methods to determine viral titers are ever-pressing.
Between preventative vaccines and palliative treatment for the sickest COVID-19 patients lies the realm of existing drugs that could be repurposed for antiviral prophylaxis.
During this webinar, Dr. Suzanne Riches highlights a variety of approaches for conducting virology assays in a high-throughput format.
Available on demand. In this informational webinar, Dr. Dmitry Kuksin, Nexcelom Senior Scientist, examines specific virology related assays such as plaque and foci formation, as well as antibody neutralization.